HKT-500 in Adult Patients With Osteoarthritis (OA) Knee Pain
Launched by HISAMITSU PHARMACEUTICAL CO., INC. · Nov 17, 2008
Trial Information
Current as of May 24, 2025
Completed
Keywords
ClinConnect Summary
The objective of this study is to demonstrate the short-term multiple dose efficacy and safety of HKT-500 in subjects with pain caused by mild to moderate osteoarthritis of the knee. The goal of the study is to gather additional information about the analgesic efficacy and safety of repeated, 24-hour applications of 2 HKT-500 patches per knee for a total of 28 days in subjects with pain caused by mild to moderate osteoarthritis of the knee.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • man or woman ≥45 years of age.
- • clinical diagnosis of unilateral or bilateral OA of the knee
- • taking an NSAID or acetaminophen on a regular basis and has a history of knee pain amelioration with NSAID or acetaminophen use.
- • mild to moderate OA of the knee at the screening visit
- • subject exhibits an arthritis "flare" in the target knee within 7 days day of withdrawing from a NSAID or acetaminophen.
- • subject understands that treatment will be administered on an inpatient basis.
- • subject is capable of understanding and complying with the protocol and has signed the informed consent document.
- Exclusion Criteria:
- • subject is a woman of childbearing potential who has a positive urine pregnancy test, is lactating, or who is not surgically sterile
- • subject has symptoms that are attributable to primary inflammatory diseases of the joint
- • subject has unstable knees including a history of the knee catching or giving way or physical examination evidence of instability
- • subject has arthropathies that occur in conjunction with systemic diseases
- • subject has a chronic pain condition
- • subject is grossly obese
- • subject has a history of knee surgery within the past 12 months or arthroscopy within the past 6 months.
- • subject has a history of osteotomies.
- • subject is not willing to discontinue the use of NSAIDs, acetaminophen or other prohibited treatments
- • subject used opioids for OA pain within 1 month
About Hisamitsu Pharmaceutical Co., Inc.
Hisamitsu Pharmaceutical Co., Inc. is a leading global pharmaceutical company based in Japan, renowned for its innovative research and development in transdermal drug delivery systems and topical therapeutic products. Established in 1847, Hisamitsu is committed to improving patient outcomes through the development of effective and safe medications for various medical conditions, including pain management and dermatological disorders. The company prioritizes clinical trials to advance its product pipeline and ensure the highest standards of efficacy and safety, aligning with its mission to enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Omaha, Nebraska, United States
Zanesville, Ohio, United States
Denver, Colorado, United States
Delray Beach, Florida, United States
San Antonio, Texas, United States
Newport News, Virginia, United States
Birmingham, Alabama, United States
Chandler, Arizona, United States
Peoria, Arizona, United States
San Diego, California, United States
Colorado Springs, Colorado, United States
Daytona Beach, Florida, United States
Fort Myers, Florida, United States
Pembroke Pines, Florida, United States
Evansville, Indiana, United States
Crestview Hills, Kentucky, United States
Fall River, Massachusetts, United States
Las Vegas, Nevada, United States
Reno, Nevada, United States
Albuquerque, New Mexico, United States
Greensboro, North Carolina, United States
Bismark, North Dakota, United States
Cincinnati, Ohio, United States
Columbus, Ohio, United States
Mogadore, Ohio, United States
Oklahoma City, Oklahoma, United States
Tulsa, Oklahoma, United States
Warwick, Rhode Island, United States
Anderson, South Carolina, United States
Austin, Texas, United States
Salt Lake City, Utah, United States
Arlington, Virginia, United States
Charlottesville, Virginia, United States
Yakima, Washington, United States
Patients applied
Trial Officials
Mr. Kenichi Furuta
Study Director
Hisamitsu Pharmaceutical Co., Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials